Samples & reference materials
FIND manages several collections, including its own and two for WHO, of well-characterized TB specimens for use by researchers, developers and manufacturers of TB diagnostics. Providing access to these specimens serves to support the development and evaluation of new and existing tools to improve TB diagnosis. Sample types range from sputum to urine, plasma and serum.
Since 2015, FIND has added strains and DNA from MDR-TB and pre-XDR-TB patients. FIND’s Virtual Strain Bank (see below) enables researchers and developers to identify strains housed at FIND.
All specimens are collected at qualified clinics, under a protocol approved by an Institutional Review Board (IRB) and with informed consent from patients meeting the inclusion criteria for sample collection. FIND follows good clinical and laboratory practice in obtaining and processing samples. If special collection methodology or sample matrix is required, requesters can email inquiries to email@example.com.
For more information on the bank, please see TB Specimen Bank FAQ.
Thanks to intensified interventions to prevent, diagnose and treat malaria, incidence of the disease decreased by an estimated 41% globally between 2000 and 2015, and by 21% between 2010 and 2015. Global malaria targets for 2030 include the reduction of malaria incidence and mortality by at least 90% compared to 2015 levels. Reaching these ambitious targets will require new, more sensitive rapid diagnostic tests to detect asymptomatic malaria infections.